Study identifier:D2550C00001
ClinicalTrials.gov identifier:NCT01754844
EudraCT identifier:N/A
CTIS identifier:N/A
A Double-blind Placebo-controlled, Randomised, Single centre, First Time in Man Study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD7624 in Healthy Subjects
Chronic obstructive pulmonary disease (COPD)
Phase 1
Yes
AZD7624, Placebo to match
All
57
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Group 1-5, single ascending dose AZD7624 Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo. | Drug: AZD7624 Single dose inhaled IMP via a nebulizer |
Placebo Comparator: Placebo Subjects will participate in 1 of 5 groups. In each group 6 subjects will receive AZD7624 and 2 subjects will receive matching placebo. | Drug: Placebo to match Single dose inhaled Placebo via a nebulizer |